Prostatype Genomics AB

As of December 31, 2023, Prostatype Genomics AB carries a market capitalization of 17.59M, placing it among publicly traded companies globally. Its enterprise value stands at 26.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2023, Prostatype Genomics AB has 1.91M shares outstanding.

These figures are as of December 31, 2023.

As of December 31, 2023, Prostatype Genomics AB maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2023.

As of the close on October 22, 2026, Prostatype Genomics AB's stock has declined approximately 63.43% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.27.

As of December 31, 2023, Prostatype Genomics AB holds 2.68M in cash and equivalents against 11.67M in total debt, resulting in a net debt position of 8.99M. Total book value stands at 24.67M, with working capital of 1.43M providing operational flexibility.

These figures cover the twelve months ended December 31, 2023.

Prostatype Genomics AB's most recent stock split took place on July 6, 2026.